Last mentioned: 19h ago
MHRA Suspension
The medicines regulator pauses the trial citing new concerns, halting the primary access route for patients.
Clinical Trial Launch
The UK government and NHS launch a formal clinical trial to gather long-term data on treatment outcomes.
NHS Routine Ban
NHS England ends the routine prescription of puberty blockers for gender dysphoria.
Cass Review Published
Final report recommends puberty blockers only be administered within a research setting due to lack of evidence.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has halted a major clinical trial into puberty blockers for minors following the emergence of new regulatory concerns. This suspension effectively closes the primary legal pathway for gender-distressed youth to access these treatments within the NHS framework.